{
  "docId": "019de076-495e-7269-8bd5-c9a0e886c917",
  "docSlug": "a4fc5169399f8913c54f14d18031629c",
  "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides",
  "authorId": "immix-biopharma",
  "authorName": "Immix Biopharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 28,
  "pageCount": 64,
  "prevPage": 27,
  "nextPage": 29,
  "slideType": "market_sizing",
  "function": "size_opportunity",
  "density": "overcrowded",
  "nDataPoints": 8,
  "notes": "Includes a comparative table of clinical outcomes (ORR/CR) for NXC-201 vs competitors.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-495e-7269-8bd5-c9a0e886c917/28",
  "deckHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917",
  "deckJsonHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917.json",
  "deckAnchorHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917#slide-28",
  "components": [
    {
      "bbox": {
        "h": 0.3,
        "w": 0.46,
        "x": 0.02,
        "y": 0.55
      },
      "kind": "chart",
      "text": "Hematologic Cancers Market Size $60B to $120B",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e59ec9d5-4cf6-46b9-974a-d0d96bfe8d94",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.46,
        "x": 0.02,
        "y": 0.28
      },
      "kind": "list",
      "text": "Hematologic cancers market opportunity is $60bn today growing to $120bn in 2028. Multiple Myeloma is 3rd most common blood cancer. AL Amyloidosis is developed by 14,982 people annually.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2572eb52-862f-4639-8e38-ef97d86d2668",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.46,
        "x": 0.52,
        "y": 0.28
      },
      "kind": "list",
      "text": "1. Leveraging market CAR-T experience. 2. Demand exceeds supply. 3. High grade side-effects with approved CAR-Ts. 4. Bispecifics/Allogeneic CAR-Ts still in progress.",
      "attrs": null,
      "subkind": "numbered",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6409332e-6aae-4deb-bdf0-9817892ab4f1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.96,
        "x": 0.02,
        "y": 0.92
      },
      "kind": "source-note",
      "text": "Sources: Multiple Myeloma life expectancy source - Arcellx July 2022 investor presentation... (full text)",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "052a4e2d-3252-463b-919b-95a9de53eb0a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.46,
        "x": 0.52,
        "y": 0.72
      },
      "kind": "table",
      "text": "Clinical performance comparison table for NXC-201 vs Allogeneic CAR-T and BCMA bispecifics.",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b0aabfde-ba36-4ac3-b094-c965d3e76efc",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.46,
        "x": 0.02,
        "y": 0.2
      },
      "kind": "title",
      "text": "Market Size",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "26cc6f25-c70a-46ec-9d32-1ca0fbf453fe",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.46,
        "x": 0.52,
        "y": 0.2
      },
      "kind": "title",
      "text": "Why Now",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "79ce3cde-c4bd-47c5-bd77-af486afd2c2c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.5,
        "x": 0.02,
        "y": 0.03
      },
      "kind": "title",
      "text": "NXC-201 Entering Large Markets At a Pivotal Moment",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a370922d-3140-4887-a064-278687a83c82",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "why_now",
      "slug": null,
      "matchId": "192b499c-fb3f-4ff2-820b-4b5e008ced04",
      "evidence": "The slide explicitly uses a 'Why Now' section to frame the market opportunity.",
      "confidence": 1
    }
  ],
  "arcBeats": [
    {
      "to": 29,
      "from": 24,
      "beatId": "fd3d2933-01c8-4f4e-b2ff-7ac84717f569",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Market Sizing",
      "beatSlug": "sequoia-pitch-market-size",
      "evidence": "The market opportunities for Immix Biopharma's therapies are discussed.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}